Erchonia®
FX 405® Laser for Pain Relief
Save on Staff Costs, Expand Treatment Range, Get the Best Results
FX 405® Laser: Fully automated machine
Only LLLT device to be FDA-cleared for chronic heel and back pain.
Erchonia’s non-thermal, Low-Level Laser Therapy (LLLT) devices are the most effective, versatile, and clinically proven technologies for pain relief. We own 22 of the 25 FDA-clearances given to Low-Level Lasers, and the efficacy of our devices has been proven by multiple (level 1) double blind, randomised, placebo-controlled, and multi-site clinical studies – the most credible research in the market today.
The treatments are short, effective, and easy to administer, saving time and minimising physical exertion. There is no associated pain or reported side effects, and the technology is very safe with no health risks. Used on their own or as an adjunct, Erchonia® lasers can be easily integrated into your current skill set, and the devices can help with a wide variety of conditions, allowing you to expand your treatment range and grow your clinic. We provide the training, ongoing support, and marketing, so you can focus on what matters most – your patients.
The FX 405 Laser scanner offers all of the same benefits
PROVEN NON-INVASIVE DRUG-FREE
About FX 405® Laser
New in series: Utilising the red (635nm) and violet (405nm) wavelengths, the FX 405® Laser offers all of the advantages of its predecessor, the FX 635®, with added benefits due to the violet wavelength: In addition to the violet wavelength’s anti-bacterial and anti-microbial properties, it produces more energy per photon – research shows that the combination of violet and red lasers results in greater pain relief. The violet wavelength also enhances the production of Reactive Oxygen Species (ROS), which play an important role in reducing pain and inflammation. > Download Brochure
How FX 405® Works
FX 405® delivers parcels of light energy into the cell which the cell can use, and the parcels are delivered in the most effective and efficient way. This added energy fuels key processes, stimulating healing, relieving pain, reducing inflammation, and restoring function. The FX 405® Laser targets complex IV in the electron transport chain and also provides antimicrobial support, optimising ATP production and enhancing cellular health. For a more detailed explanation, please see the ‘What Is the Technical Explanation for How Erchonia® Lasers Work?’ FAQ below.
Whatever you do, do it well.
PROVEN NON-INVASIVE DRUG-FREE
For over two decades, Erchonia has been committed to the research of low
level laser therapy (LLLT) through extensive clinical studies and has attained
more than (20) FDA indications for use. Erchonia made history in 2002
when the FDA granted Erchonia market clearance for the first non-thermal
laser in history. This created a new category for the FDA called NHN Laser,
making Erchonia the gold standard for low level laser technology.
Case Studies
Erchonia® lasers can help a wide variety of patients, including: Orthopaedic pain – sprains, whiplash, muscular pain, cervical or lumbar radiculopathy, tendinitis, and carpal tunnel syndrome. Our devices have also shown positive effects on individuals with chronic conditions like arthritis and osteoarthritis, and in treating post-surgical pain; Neuropathic pain, including various types of neuralgia and diabetic neuropathy; Pain management for athletes recovering from training or injuries.
The most researched non-invasive lasers in the world.
Toucheless & Unattended Technology
Recent Testimonials
From chiropractors and physiotherapists, to physicians and surgeons, to professional sports clubs and sports medicine practises, here’s what our clients have to say about our medical-grade Low-Level Lasers.
What we love about the Erchonia non-thermal lasers is that they utilise electromagnetic energy transfer. This enables healing at a cellular level. Their lasers have enabled us to treat tissue injury and reduce pain in the most efficacious manner vs other modalities available. The addition of the Erchonia laser system has revolutionised our practises and allowed us to attain never seen before patient outcomes.
